Resources Repository
-
ArticlePublication 2021Employee Health Plans Powered by Analytics
This article describes a business model for the employee health plans of large firms to …
This article describes a business model for the employee health plans of large firms to bypass insurers and instead use direct contracts with hospitals which have been designated as centers of excellence. The authors propose methods of machine learning and data analytics to identify efficient and effective delivery systems, with the ultimate goal of improving health care quality.
North America | Health Systems | Operations Research -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
North America | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
North America | Infectious Diseases | Value of Information | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Europe -
ArticlePublication 2022Early HPV Natural History Transitions
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on …
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on accurate transition risks for human papillomavirus (HPV) infection, persistence (or absence of HPV clearance), progression to precancerous lesions, and invasion. To inform the refinement of such models, we compared the early natural history of HPV types using prospective data from immunocompetent women in the Guanacaste Natural History Study, the ASCUS-LSIL Triage Study, and the Costa Rica HPV Vaccine Trial. We…
North America | Infectious Diseases | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Latin America & Caribbean -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
North America | Infectious Diseases | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
North America | Infectious Diseases | Preferences/Values | Benefit-Cost Analysis | Policy/Regulation | Government/Law -
ArticlePublication 2021COVID and the Age–VSL Relationship
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions …
In this article, the researchers explore the approach used to value COVID-19 mortality risk reductions in analyses of lockdowns and other policies. Many rely on a population-average estimate of the value per statistical life (VSL); others adjust VSL for life expectancy at the age of death. The article explores the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain; these uncertainties in turn may affect whether the…
North America | Infectious Diseases | Preferences/Values | Benefit-Cost Analysis | Government/Law | Health/Medicine -
Online LearningVideo, Teaching Resource 2021Reporting on COVID-19 Vaccines at the Intersection of Science and Politics
Journalists play a vital role in communicating to the public about COVID-19 vaccines, and currently …
Journalists play a vital role in communicating to the public about COVID-19 vaccines, and currently under challenging circumstances. The science surrounding COVID-19 is rapidly changing, vaccines have been developed at “warp speed” using a new approach, and misinformation is on the rise. Moreover, current and historical injustices and inequities, as well as heightened political polarization, affect what information is consumed, trusted, and acted upon. This webinar offers an opportunity for members of the media to…
North America | Infectious Diseases | Decision Psychology | Preferences/Values | Social Determinants | Policy/Regulation | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2021National Academies Work Helps Foster an Evidence-Based Information Environment
U.S. Surgeon General Vivek Murthy issued a public advisory on health misinformation, calling it a …
U.S. Surgeon General Vivek Murthy issued a public advisory on health misinformation, calling it a “serious threat to public health” and encouraging all Americans to help slow its spread during the COVID-19 pandemic and beyond. To that end, the National Academies have been addressing misinformation in health and science on multiple fronts and are taking steps to help cultivate a fact- and evidence-based information environment. This description was extracted from the article.
North America | Infectious Diseases | Decision Psychology | Preferences/Values | Social Determinants | Policy/Regulation | Culture/Society | Health/Medicine | Science/Technology